Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2157-2161

  Okamura, Yoshikazu ^a   Yokoi, Hiroyuki ^a  

^a LSI MEDIENCE CORPORATION   (Japan)

Author keywords

CLEIA; PATHFAST; POCT; Presepsin; SCD14 ST; Sepsis

Indexed keywords

BILIRUBIN; HEMOGLOBIN; LIPID; PLASMA PROTEIN; PRESEPSIN; RHEUMATOID FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT; NORMAL HUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ANTIGENS, CD14; HUMANS; LIMIT OF DETECTION; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS;

EID: 80053638923     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.024     Document Type: Article

References (21)

1. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
2. Battleman D.S., Callahan M., Thaler H.T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med 2002, 162(6):682-688.
3. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
4. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345(19):1368-1377.
5. Rangel-Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273(2):117-123.
6. Bhatia B.D., Basu S. Newer diagnostic tests for bacterial diseases. Indian J Pediatr 2007, 74(7):673-677.
7. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15(6):581-587.
8. Christ-Crain M., Müller B. Procalcitonin in bacterial infections-hype, hope, more or less?. Swiss Med Wkly 2005, 135(31-32):451-460.
9. Yaegashi Y., Shirakawa K., Sato N., et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11(5):234-238.
10. Meisner M. Procalcitonin: Erfahrungen mit einer neuen Messgroesse fuer bakterielle Infektionen und systemische Inflammation. J Lab Med 1999, 23:263-272.
11. Kojika M., Takahashi G., Matsumoto N., et al. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Medical Postgraduates 2010, 48(1):46-50.
12. Takahashi G., Suzuki Y., Kojika M., et al. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Medical Postgraduates 2010, 48(1):19-24.
13. Shirakawa K., Naitou K., Hirose J., et al. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 2011, 49(5):937-939.
14. Kurihara T., Yanagida A., Yokoi H., et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008, 375(1):144-146.
15. Furusako S, Shirakawa K, Methods for detecting human low molecular weight CD14. United States patent 2008;US7465547 B2.
16. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009;US7608684 B2.
17. Bablok Passing H. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J. Clin. Chem. Biochem. 1983, 21(11):709-720.
18. CLSI Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. NCCLS document 2004, EP17-A.
19. CLSI Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition. NCCLS document 2004, EP5-A2.
20. Shozushima T., Takahashi G., Matsumoto N., Kojika M., Okamura Y., Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011 May, 12. 10.1007/s10156-011-0254-x.
21. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327.